 | |
| Clinical data | |
|---|---|
| Trade names | Minnebro |
| Other names | CS-3150; XL-550 |
| Routes of administration | By mouth |
| Drug class | Antimineralocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H21F3N2O4S |
| Molar mass | 466.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Esaxerenone (INNTooltip International Nonproprietary Name) (brand nameMinnebro; developmental code namesCS-3150,XL-550) is anonsteroidalantimineralocorticoid which was discovered byExelixis and developed byDaiichi Sankyo Company and is approved inJapan for the treatment ofhypertension.[1][2][3] It acts as a highlyselectivesilent antagonist of themineralocorticoid receptor (MR), thereceptor foraldosterone, with greater than 1,000-fold selectivity for this receptor over othersteroid hormone receptors, and 4-fold and 76-fold higheraffinity for the MR relative to the existing antimineralocorticoidsspironolactone andeplerenone.[1][2][3]
Daiichi Sankyo Company, Limited on January 8, 2019 announced the receipt of marketing approval in Japan for MINNEBROTM Tablets 1.25 mg, 2.5 mg and 5 mg (generic name: esaxerenone) for the treatment of hypertension. As of January 2019, esaxerenone is inphase IIIclinical trials fordiabetic nephropathies.[1][4]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
